Ovarian Cancer

A pharmaceutical company initiated a phase 1b study in patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.

Social media, including Facebook groups, can help connect patients with rare cancers like granulosa cell tumors to researchers, allowing them to learn more about disease management.

Interim findings from a clinical trial showed that adding Lynparza and Imfinzi to an Avastin and chemotherapy regimen tended to improve the time patients lived before their disease got worse.

Twenty-five years ago, I was diagnosed with ovarian cancer, which sparked fears of leaving my loved ones behind.

The temporary tattoos that guided the radiation for my cancer treatment were not beautiful, artistic or cool — they were more than that.

Positive results have emerged from a trial testing PIPAC, a procedure used for appendiceal, ovarian, gastric and colon cancers that works by spraying chemotherapy directly onto tumors.

After promising phase 1 results, ART0380 will be studied in a randomized phase 2 trial for patients with platinum-resistant ovarian cancer.

I’m coming up on my 10-year cancer anniversary, and it feels bittersweet.

Women with low-grade serous ovarian cancer treated with avutometinib and defactinib experienced positive response rates compared with avutometinib alone.

The trial is evaluating the safety and efficacy of AVB-001 patients with relapsed refractory ovarian cancer.

Women who were taking beta-blockers, a medicine to treat heart conditions like high blood pressure, among others, near the time of surgery for epithelial ovarian cancer may confer a survival benefit years after undergoing a procedure.

One expert said that the FDA approval of the antibody-drug conjugate Elahere represents a new treatment option for patients with folate receptor alpha-positive, platinum resistant ovarian cancer.

Researchers running clinical should be aware of how these new drugs affect our day-to-day lives — not just in the big ways, but also the small ones that take their toll over the long haul.

Women who face menopause after a cancer diagnosis may be able to manage their symptoms without relying on estrogen-based therapies, although discussing this with a cancer team will help patients find what’s best for them.

From the death of standup comedian and "Love Goddess" Judy Tenuta to professional sports hall-of-famers discussing their cancer, here’s what’s happening in the cancer space this week.

The novel drug PY159 will be studied as a single agent and in combination with Keytruda for patients with certain solid tumors — including ovarian, pancreatic, lung, head and neck, colorectal and breast cancers.

The OnPrime trial will investigate if adding Olvi-Vec, a modified virus, to chemotherapy and Avastin will improve outcomes for pretreated platinum-resistant or refractory ovarian cancer.

Although maintenance treatments have helped patients with ovarian cancer live longer, experts note there are still some unmet needs that must be addressed.

BNT211-01, a novel CAR-T cell therapy, was efficacious in treating patients with CLDN6-positive, relapsed/refractory solid cancers, according to a small clinical trial.

Rubraca improved progression-free survival in patients with BRCA1/2-mutant, platinum-sensitive, relapsed ovarian cancer, according to findings from the ARIEL4 clinical trial.

The first patient was treated in a phase 2 trial assessing the safety and efficacy of navicixizumab, with or without chemotherapy, in colorectal, gastric, ovarian and breast cancer.

I am still here fighting, fighting hard and I will continue to do so to make sure I have more graduations, more weddings, and more everything that I can squeeze into my precious time left here on earth.

Adding Rivoceranib to pegylated liposomal doxorubicin — a type of chemotherapy — improved survival outcomes for patients with platinum-resistant ovarian cancer, according to recent study results.

There are many people in my life who made my cancer experience far easier. I call them my "cancer posse."

Treatment with Gen-1, a novel gene therapy, resulted in a 33% improvement in progression-free survival for patients with advanced ovarian cancer, according to recent study findings.

The study the FDA allowed to continue is investigating the safety and efficacy of the novel cancer drug ACR-368 in patients with endometrial, urothelial and ovarian cancer.

The use of Jakafi plus chemotherapy shows promise in the pre- and post-surgical treatment settings for patients with stage 3 and 4 ovarian cancer, warranting further study of the combination.

It’s good to have all the facts when you decide whether to participate in a cancer drug clinical trial—even the ones that make you swallow hard and tear up.

A clinical trial just launched to study Vaxinia — a novel cancer vaccine — in patients with previously treated advanced solid tumors.

For patients with advanced epithelial ovarian cancer, there were little — if any — differences in survival outcomes depending on when they received surgery.